Oral phentolamine (Vasomax®)

Drugs of Today

Volumn 36, Issue 2-3, 2000, Pages 121-124

  Brock, Gerald ^a  

^a ST JOSEPH S HEALTH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PHENTOLAMINE;

CARDIOVASCULAR DISEASE; CONFERENCE PAPER; DRUG APPROVAL; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; ERECTILE DYSFUNCTION; GASTROINTESTINAL SYMPTOM; HUMAN; MALE;

EID: 0034026518     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2000.36.2-3.568785     Document Type: Conference Paper

References (23)

1. Nickerson, M. The pharmacology of adrenergic blockade. Pharmacol Rev 1949, 1: 27-101.
2. Trapold, J.H., Warren, M.R., Woodbury, R.A. Pharmacological and toxicological studies on 2-(N-p-tolyl-N-(m-hydroxyphenyl)-aminomethyl)-imidazoline (C-7337), a new α-adrenergic blocking agent. J Pharmacol Exp Ther 1950, 100: 119-27.
3. Raja, S.N., Treede, R.D., Davis, K.D., Campbell, J.N. Systemic α-adrenergic blockade with phentolamine: A diagnostic test for sympathetically maintained pain. Anesthesiology 1991, 74: 691-8.
4. Taylor, S.H., Sutherland, G.R., Mackenzie, G.J., Staunton, H.P., Donald, K.W. The circulatory effects of intravenous phentolamine in man. Circulation 1965, 31: 741-54.
5. Taylor, S.H., Sutherland, G.R., Mackenzie, G.J., Staunton, H.P., Donald, K.W. The circulatory effects of phentolamine in man with particular respect to changes in forearm blood flow. Clin Sci 1965, 28: 265-84.
6. Gould, L., Reddy, C.V.R. Phentolamine. Am Heart J 1976, 92: 397-402.
7. Zahir, M., Gould, L. Phentolamine and β-adrenergic receptors. J Clin Pharmacol 1971, 11: 197-203.
8. Singh, J.B., Hood, W.B., Abelmann, W.H. Beta mediated inotropic and chronotropic actions of phentolamine. Am J Cardiol 1970, 26: 660.
9. Bagwell, E.E., Hilliard, C.C., Daniell, H.B., Taylor, P.L., Walton, R.P. Studies on the inotropic mechanism of phentolamine. Am J Cardiol 1970, 25: 83.
10. Dunne, M.J. Block of ATP-regulated potassium channels by phentolamine and other α-adrenoceptor antagonists. Br J Pharmacol 1991, 103: 1847-50.
11. Parker, J.D., Newton, G.E., Landzberg, J.S., Floras, J.S., Colucci, W.S. Functional significance of presynaptic α-adrenergic receptors in failing and nonfailing human left ventricle. Circulation 1995, 92: 1793-800.
12. Gould, L. Additional information on solving the riddle of phentolamine's action. Circulation 1996, 94: 586.
13. Regitine® phentolamine USP (product labelling). CIBA Pharmaceutical Company, 1981.
14. Warren, M.R., Woodbury, R.A., Trapold, J.H. Pharmacological studies on 2-{N-p-tolyl-N-(m-hydroxyphenyl)-animomethyl}-imidazoline hydrochloride (C-7337). Fed Proc 1949, 8: 343.
15. Shir, Y., Cameron, L.B., Raja, S.N., Bourke, D.L. The safety of intravenous phentolamine administration in patients with neuropathic pain. Anesth Analg 1993, 76: 1008-11.
16. Montorsi, F., Guazzoni, G., Rigatti, P., Pozza, G. Pharmacological management of erectile dysfunction. Drugs 1995, 50: 465-79.
17. Stief, C.G., Wetterauer, U. Erectile responses to intracavernous papaverine and phentolamine administration in patients with neuropathic pain. Anesth Analg 1993, 76: 1008-11.
18. Gwinup, G. Oral phentolamine in nonspecific erectile insufficiency. Ann Intern Med 1988, 109: 162-3.
19. Zorgniotti, A.W. "On demand" oral drug for erection in impotent men. J Urol 1992, 147(4): Abst 382.
20. Zorgniotti, A.W. Experience with buccal phentolamine mesylate for impotence, Int J Impot Res 1994, 6: 37-41.
21. Becker, A.J., Stief, C.G., Machtens, S. et al. Oral phentolamine as treatment for erectile dysfunction. J Urol 1998, 159: 1214-6.
22. Becker, A.J., Stief, C.G., Machtens, S. et al. Double-blind study on oral phentolamine as treatment for erectile dysfunction. J Urol 1997, 157(4, Suppl.): Abst 785.
23. Porst, H., Derouet, H., Idzikowski, M. et al. Oral phentolamine (Vasomax™) in erectile dysfunction - Results of a German multicenter study in 177 patients, Int J Impot Res 1996, 8: 117.